ELI LILLY & Co is 312.7x more valuable than NewAmsterdam Pharma Company N.V. by market capitalization ($1.072 T vs $3.43 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NAMS | LLY |
|---|---|---|
| Market cap | $3.43 B | $1.072 T |
| US-listed rank | #1703 | #10 |
| Revenue (latest FY) | $22.50M | $65.18B |
| Net income (latest FY) | -$203.00M | $20.64B |
| Net margin | -902.1% | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 386 | 989 |
ELI LILLY & Co is 312.7x more valuable than NewAmsterdam Pharma Company N.V. by market capitalization ($1.072 T vs $3.43 B).
In their latest fiscal years, NewAmsterdam Pharma Company N.V. reported $22.50M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: NewAmsterdam Pharma Company N.V. and ELI LILLY & Co, or browse the full rankings.